Segment Data

3 Months Ended

Mar. 31, 2024

Segment Data

Segment Data

14. Segment Data

The Company has two reportable segments- animal health and human health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing human products and the ongoing commercialization of Mytesi, which the U.S. FDA approves for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company's reportable segments net revenues and net loss for the three months ended March 31, 2024, and 2023 consisted of the following:

	Three Months Ended
	March 31,
	2024		2023
(in thousands)	(unaudited)
Revenue from external customers
Human Health	$	2,303	$	1,927
Animal Health		48		45
Consolidated Totals	$	2,351	$	1,972
Segment net loss
Human Health	$	(4,601)	$	(6,539)
Animal Health		(4,767)		(5,858)
Consolidated Totals	$	(9,368)	$	(12,397)

The Company's reportable segments assets consisted of the following:

	March 31,		December 31,
	2024		2023
(in thousands)	(unaudited)
Segment assets
Human Health	$	42,154	$	42,289
Animal Health		163,555		153,190
Total	$	205,709	$	195,479

The reconciliation of segments assets to the consolidated assets is as follows:

	March 31,		December 31,
	2024		2023
(in thousands)	(unaudited)
Total assets for reportable segments	$	205,709	$	195,479
Less: Investment in subsidiary		(29,232)		(29,232)
Less: Intercompany loan		(121,088)		(115,484)
Consolidated Totals	$	55,389	$	50,763